



## Aptinyx to Present at Upcoming Virtual Investor Conferences

EVANSTON, Ill., June 16, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following upcoming investor conferences:

- **2020 BMO Prescription for Success Healthcare Conference** on Tuesday, June 23, 2020 at 2:30 p.m. ET and;
- **SVB Leerink CybeRx Series: 2<sup>nd</sup> Annual CNS Forum** on Wednesday June 24, 2020 at 1:15 p.m. ET.

A live webcast of each presentation will be available on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at <https://ir.aptinyx.com>. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

### About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit [www.aptinyx.com](http://www.aptinyx.com).

### Forward-Looking Statements

*Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company’s business plans and objectives, including therapeutic effects of the company’s product candidates and discovery platform. Risks that contribute to the uncertain nature of the forward-looking statements include: the effect of COVID-19 on our business and financial results, including with respect to disruptions to our clinical trials, business operations, and ability to raise additional capital; the success, cost, and timing of the company’s product candidate development activities and planned clinical studies; the company’s ability to execute on its strategy; the company’s estimates regarding expenses, future revenue, and capital requirements; as well as those risks and uncertainties set forth in the company’s most recent annual report on Form 10-k and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press*

*release speak only as of the date on which they were made. Aptinix undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.*

**Investor and Media Contact:**

Nick Smith

Aptinix Inc.

[ir@aptinix.com](mailto:ir@aptinix.com) or [corporate@aptinix.com](mailto:corporate@aptinix.com)

847-871-0377



Source: Aptinix Inc.